Beam Therapeutics Inc., a firm in the biotechnology sector focusing on the creation of exact genetic treatments via base editing, declared that the first patient received BEAM-201 treatment.

This article summarized the latest R&D progress of Metyrapone, the Mechanism of Action for Metyrapone, and the drug target R&D trends for Metyrapone.

The Angiotensin II receptor plays a crucial role in the human body by regulating blood pressure and fluid balance.

Eledon Pharmaceuticals, Inc. revealed that it has administered the initial dose to the first participant in the BESTOW Phase 2 study.

Ipsen SA is a pharmaceutical organization that was founded in 1929 and is based in France.

uniQureN.V.,announces that their AMT-260 Gene Therapy candidate, developed for the treatment of Refractory Mesial Temporal Lobe Epilepsy, has received approval for the Investigational New Drug Application from the FDA.

This article summarized the latest R&D progress of Magrolimab, the Mechanism of Action for Magrolimab, and the drug target R&D trends for Magrolimab.

Angiotensin-converting enzyme 2 (ACE2) is a key enzyme in the Renin-Angiotensin System (RAS), acting as a regulating factor for the ACE-Angiotensin II (Ang II)-Ang receptor I (AT1) axis, maintaining the balance of the RAS system.

Wave Life Sciences Ltd. declared today its initial CTA submission for WVE-006 in cases of alpha-1 antitrypsin deficiency AATD.

Ionis Pharmaceuticals, Inc. is a biopharmaceutical company that was founded in 1989 and is headquartered in California, United States.

X4 Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for the approval of once-daily oral mavorixafor in the treatment of WHIM syndrome.

This article summarized the latest R&D progress of Rilonacept, the Mechanism of Action for Rilonacept, and the drug target R&D trends for Rilonacept.